Tuberculosis (TB) is the most common opportunistic infection in HIV-infected people. In 2010 the association between these diseases resulted in up to 1.2 million (12 -14%) new TB cases among HIVinfected people and the death of 0.35 million HIV/TB co-infected patients. 1 The scale-up of combination antiretroviral therapy (cART) in the developing world is rapidly progressing, improving survival of HIV-infected people. While cART effectively reduces TB risk in HIV-infected persons, 2 TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) has emerged as an important early cART complication, reflecting that TB immune responses contribute to both protection and pathology. Two TB-IRIS forms are recognised: (i) paradoxical, in patients established on TB treatment before cART, who manifest with recurrent or new TB symptoms and clinical features after cART initiation; and (ii) lesser-characterised unmasking TB-IRIS, in patients not receiving treatment for TB when cART is started, but who present with active TB within 3 months of initiation, with heightened intensity of clinical manifestations, and marked inflammatory features. 3, 4 Recently we studied the regenerating TB-specific T-cell immune responses in Mycobacterium tuberculosis (MTB)-sensitised adults over 12 months following commencement of cART. We showed that, in overall improved TB antigen-specific immunity, it is the central memory T-cell response that best correlates with increased cART-mediated immunity. 5 A single patient in this cohortexcluded from analysis -was diagnosed with overt pulmonary TB having commenced cART. We were therefore presented with the opportunity to undertake detailed immunological analysis of a case that we considered as unmasking TB-IRIS. Tuberculin-specific Th1-responses were expanded during, but not before, the IRIS episode. We found a distorted balance between central memory and effector memory T-cells at cART commencement that might have predisposed the patient to unmasking TB-IRIS.
Methods
The study was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee (FHS HREC 336/2004). HIV-infected adults were recruited at G F Jooste Hospital (GFJH), Cape Town, at the start of cART (day 0), and followed up at weeks 2, 4, 12, 24, 36 and 48, as described in detail. 5 Venous blood (30 ml) was obtained at each time-point for separating peripheral blood mononuclear cells (PBMC) and serum.
For comparison in some instances we included a subset of 5 patients (3 female, 2 male, median age 36 years, median nadir CD4 count 42), recruited for a previously published prospective longitudinal study; 6 all developed paradoxical TB-IRIS within a median of 14 days of commencing cART.
T-cell phenotyping was performed using fresh PBMC following overnight stimulation with purified protein derivative (PPD; Statens Serum Institute, Denmark) and staining for various cell-surface Background. Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an early complication of combination antiretroviral therapy (cART). Two forms are recognised: (i) paradoxical -recurrent or new TB symptoms develop after cART initiation in patients receiving TB treatment prior to cART; and (ii) unmasking TB-IRIS -active TB presents within 3 months of cART in patients not receiving TB treatment at cART initiation. The latter has heightened clinical manifestations and a marked inflammatory presentation.
Aim. To gain insight into the immune pathogenesis of a case of unmasking TB-IRIS.
Methods. The patient was recruited when starting cART and followed up at 4, 12 and 24 weeks of treatment. Peripheral blood mononuclear cells were used for flow cytometry.
Results. Immunological analysis indicated increased CD4 + T-cell proportions from 1.1% at baseline to 14% at 24 weeks (the CD4 count increased from 4 cells/µl at baseline to 41 cells/µl at 24 weeks). HIV viral load fell from 460 774 to 1 405 copies/ml during the same We found a distorted balance between central memory and effector memory T-cells at cART commencement that might have predisposed the patient to unmasking TB-IRIS. We showed that this might have reflected compromised thymic output.
Discussion. While it has been suggested that tuberculin-specific Th1-responses induce TB-IRIS in HIV co-infected patients, our data in this case indicated that these cells were expanded only after IRIS onset and were therefore not inducing TB-IRIS.
Conclusion. We describe, in hitherto unpublished detail, the immunological characterisation of an unmasking TB-IRIS case; we show that thymic output may be compromised at IRIS onset. markers and intracellular cytokines as described, 5 using a BD FACS Calibur Flow Cytometer. Data analysis was performed using FlowJo Cytometry Analysis software (TreeStar Inc, Stanford University, FlowJo Africa scheme).
Serum thymulin was determined by enzyme-linked immunosorbent assay (ELISA) (PromoKine, PromoCell Gmbh, Germany) according to the manufacturer's recommendations.
Statistical analysis was performed using GraphPad Prism (version 5.0a). Data normality was assessed with the D' Agostino & Pearson test. Results are quoted as medians with inter-quartile range (IQR).
Results

Patient clinical characterisation
The subject of the current report, one of 28 in our previous study, 5 His CD4 count prior to cART was 4 cells/µl and HIV viral load was 460 774 copies/ml.
The patient reported no symptoms on the day of commencement of cART: stavudine 30 mg 12-hourly, lamivudine 150 mg 12-hourly and efavirenz 600 mg nocte. He reported no new symptoms and good cART adherence 2 weeks after initiation. However, at week 4 he showed symptoms of active TB: a productive cough, progressive dyspnoea on exertion of 6 days' duration and diarrhoea, 3 kg of weight loss in 2 weeks (weight 48.5 kg), febrile and pale appearance, respiratory distress, and hepatomegaly. A chest radiograph showed bilateral extensive mid-zone infiltrates and right hilar lymphadenopathy. Sputum direct microscopy (3+ acid-fast bacilli) confirmed MTB and the culture was positive (susceptible to rifampicin and isoniazid). He was admitted to GFJH and recommenced on anti-TB therapy (isoniazid, rifampicin, ethambutol, pyrazinamide and streptomycin initially). Corticosteroids were not prescribed. His symptoms resolved within 2 weeks: 12 weeks post cART initiation he weighed 50.5 kg and his CD4 count increased to 38 cells/mm 3 ; by 24 weeks his weight increased to 56 kg, his CD4 count to 41 cells/mm 3 and his HIV viral load decreased to 1 405 copies/ml.
Immunological characterisation
Immunophenotyping by flow cytometry was undertaken at day 0, and 2, 4, 12 and 24 weeks post cART initiation (Table 1) . Results are presented as a comparison with the median and IQR values from the 19-patient comparison group previously described. 5 The patient started cART with a very low CD4 count (4 cells/mm 3 ), reflected by the CD4 + T-cell proportions in flow cytometry: 1.1% of PBMC were positive for CD4 on day 0, remaining lower than the median of the comparison group up until 24 weeks, when it became similar at 14%. On the other hand, the proportion of CD8 + T-cells (% of PBMC) was comparable to and within the IQR of the comparison group at day 0, 2 and 4 weeks of cART. Interestingly, at 12 weeks (after the IRIS episode) the patient's CD8 + T-cell proportions fell to just 27.4%, rising again to 53% at 24 weeks.
Cellular phenotypes in the peripheral blood
The proportion of effector CD4 + CCR5
+ T-cells was relatively high (Table 1) : 11.8% on day 0, falling to 0.5% at 4 weeks, and a large expansion to 53.9% at 12 weeks. These dynamic changes were also reflected in proportional changes of differentiated CD4 cells that lack CD27 and CCR7, expanding to 72.3% at 12 weeks. -to 71.4%. After IRIS resolution at 12 weeks, these cells had proportionally and sharply declined to 14.7 and 13%, respectively, well below the median observed in the comparison group.
The least differentiated CD27 + CD45RA + CD4 + T-cells were proportionally elevated at cART initiation (27% at day 0, double the 13.1% median of the comparison group) and fell to 2.9% at week 4 (IRIS onset). This was followed by a slow increase to 6.9% at week 12 and a large expansion to 42% at week 24.
Cellular activation was increased in the patient's blood from day 0, with CD4 + CD69
+ cells reaching a peak of 19.4% at 4 weeks (IRIS onset), remaining elevated at week 12 (10.7%), and declining to levels similar to the comparison group by week 24 (Table  1) . Similarly, CD4 + CD25
+ T-cells were proportionally elevated at weeks 4 (3.8%) and 12 (6.6%), with a further increase to 9.9% at week 24. The proportion of CD4 + CD25 + T-cells expressing interleukin (IL)-10 (regulatory cells) was slightly elevated from the start of cART and increased to 5.3% at 12 weeks, compared with the almost undetectable levels in the comparison group throughout the longitudinal follow-up.
PPD-specific cytokine-producing T-cells during IRIS Effector function of the CD4
+ T-cells, determined by intracellular cytokine staining for IFN-γ in response to PPD stimulation, was found to be only 0.4% at cART initiation, remaining at similar levels at weeks 2 and 4 (when IRIS was diagnosed). However, there was an increase to 7.8% at week 12, in line with the expansion of effector (Table 1) .
Distorted balance between CD4 memory phenotypes
The overall dynamics of CD4 T-cell phenotypes indicated that, between cART initiation and IRIS onset, the central memory T-cells proportionally and rapidly increased and effector T-cells proportionally fell, leading to a distorted balance between T-cell phenotypes. The ratio between the 2 subsets (% CD4 (Fig. 3A) indicated a rise from 1.1 at day 0 to 156 at week 4 (IRIS onset), and a fall to 0.3 at 12 weeks (after IRIS resolution). The comparative median ratios in the comparison group were relatively stable over time (7, 7.2 and 9.7 at weeks 0, 4 and 12, respectively). The least differentiated CD27 + CD45RA + CD4 + T-cells were proportionally over-represented in the patient's blood at cART initiation (27%), compared with the 19 patients who did not develop TB during the first year of cART (Table 1) . We hypothesised that this could be due to increased T-cell turnover as a result of decreased thymic output, as previously suggested. 7 Thymic output can be approximated through the ratio of naïve/memory T-cells. 8 We found the ratio of percentage CD4 (Fig. 3B) . For further investigation, an alternative method of quantifying thymic output was employed. Thymulin (formerly called serum thymic factor) is a nonapeptide hormone secreted by human thymic epithelial cells and is essential for T-cell differentiation. 9 Its production is stimulated by prolactin and growth hormones and it is detectable in serum by ELISA. 10 The serum thymulin concentration in 13/19 patients with no adverse events during cART was higher (median 406 pg/ml, IQR 356 -507) than that of the unmasking TB-IRIS patient at week 4 (223 pg/ml; Fig. 4A ). We confirmed this finding by determining serum thymulin concentrations in 5 patients, previously recruited for a prospective longitudinal analysis, 6 all of whom developed paradoxical TB-IRIS within 14 days of cART commencement. We found significantly lower serum thymulin concentrations in TB-IRIS patients at the time of IRIS compared with baseline levels (Fig. 4B) : 382 pg/ml (IQR 323 -441 pg/ml) at day 0 v. 316 pg/ml (IQR 248 -386 pg/ml) at day 14 (p=0.03, Wilcoxon-matched pairs test). Further comparison of the 19-patient group with no adverse events (representing protective immune reconstitution) with the group with TB-IRIS (representing pathogenic immune reconstitution) indicated that, while there was no difference in thymulin concentrations at baseline (p=0.23, day 0), there was a significant difference between the groups at IRIS onset (p=0.009, day 14). Overall, these data indicate that thymic output may be significantly compromised at IRIS onset.
Discussion
TB is the most common opportunistic infection in HIV-infected patients in Africa and reaches its highest incidence within the first 3 months of cART commencement. It has been proposed that all TB diagnosed when ART is concurrent should be termed ART-associated TB. 11 However, TB that presents soon after ART initiation due to restoration of TB antigenspecific immune responses has been termed 'unmasking TB' , and a subset of these patients presenting with heightened clinical manifestations within the first 3 months of ART are regarded as having 'unmasking TB-IRIS' . 2 There have been less cases of unmasking TB-IRIS reported compared with paradoxical TB-IRIS, due to difficulties in diagnosis. It is accepted that TB-IRIS is a clinical syndrome resulting from the exaggerated inflammatory response towards the antigens of MTB in the context of a recovering immune response. However, the immunopathogenesis of this immune reaction is less well understood.
Although the immunopathogenesis of paradoxical TB-IRIS has been related to the expansion of PPD-specific IFN-γ-secreting CD4 T-cells during cART, we described similar CD4 T-cell expansions in TB-IRIS and non-IRIS control patients, bringing into question the causality of these expansions. 6 The present case presented a unique opportunity to elucidate further the immunopathogenesis of unmasking TB-IRIS. Our data show that the PPD-specific IFN-γ-secreting CD4 T-cells expanded after resolution of the IRIS episode (at 12 weeks, when the patient improved).
T-cells undergo a unique developmental programme after activation, resulting in the generation of memory and effector T-cells. The sequence of differentiation remains unclear in humans but telomere length supports a linear pathway. 12 Macaque studies also support the linear differentiation pathway from naïve, to central memory, to effector memory, with terminally differentiated cells representing the end stage. 13 Our data show a relatively large proportion of undifferentiated CD4 T-cells at the time of cART initiation, leading on to the expansion of central memory cells at 4 weeks, and subsequent expansion of effector and terminally differentiated effector cells at 12 weeks. This coincides with the expansion of effector function (cytokine secretion) with intracellular staining being highest for all 4 cytokines studied (IFN-γ, IL-2, IL-10 and TNF) at 12 weeks. The Th1 expansions associated with this case of unmasking TB-IRIS appear to be a consequence of the syndrome, and possibly due to the distorted proportional balance between memory T-cell phenotypes at the time of staring cART. Only the blood compartment was studied in this patient; therefore, we cannot exclude that the distorted balance is not attributed to sequestration in mycobacterial infection sites.
It is widely accepted that patients with high viral loads and low CD4 counts are at the highest risk of developing all forms of TB-IRIS.
2,11
Studies of T-cell dynamics during HIV infection have shown that the higher the viral load, the greater the rate of CD4 T-cell destruction, hence the requirement for immune system reconstitution; this is dependent on the reconstitution of naïve CD4 T-cells, which in turn depends on thymic output. 7 HIV-infected patients receiving cART and undergoing protective immune reconstitution, show a progressive increase in naïve T-cell numbers related to thymic function.
14 A quantitative measure of thymic function is achieved by assaying the nonapeptide hormone thymulin produced by thymic epithelial cells. 9 HIV-infected individuals show a progressive decline of circulating thymulin levels. 15 Here we show that the serum thymulin concentration was higher in patients with protective immune reconstitution, compared with this unmasking TB-IRIS case, especially at the time of IRIS diagnosis. We further confirmed in a larger group of patients with pathogenic immune reconstitution that thymic function is significantly compromised at the time of IRIS onset, as reflected by lower serum thymulin concentrations. Serum thymulin concentration in patients at highest risk for developing TB-IRIS warrants further study.
There are several limitations to our study: (i) the absence of MTB culture at the end of the initial course of TB treatment to confirm treatment success, (ii) the lack of viral load at timepoints other than at day 0 and 6 months of cART, and (iii) the lack of longitudinal follow-up beyond 6 months. However, the marked inflammatory component, as illustrated by the expansion of activation and inflammatory markers (CD69 and TNF) on CD4 T-cells, supports the diagnosis of unmasking TB-IRIS in our study.
Fig. 2. Flow cytometry plots illustrating the intracellular cytokine-secreting phenotype of CD4 + cells at 12 weeks of cART (8 weeks after IRIS onset). CD4
+ lymphocytes were selected and gated on intracellular cytokines IL-2, TNF and IL-10.
Fig. 4. (A) Longitudinal evaluation of serum thymulin concentration in 13 patients with no adverse events during cART (open circles) compared with the unmasking TB-IRIS case (illustrated in red). (B) Comparison of the same 13 patients (no IRIS, open circles) with 5 paradoxical TB-IRIS patients (IRIS, black circles) and the unmasking TB-IRIS case (red) at day 0 and 14 of cART.
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Conclusion
We describe, in hitherto unpublished detail, the immunological characterisation of an unmasking TB-IRIS case, showing that immune changes may be linked to the distorted homeostatic balance between T-cell memory phenotypes at the time of cART initiation. We provide evidence that this distorted balance may reflect compromised thymic output in patients who are most at risk of developing immune reconstitution disease.
